Elanco Shareholders Approve Board and Compensation Plans

An announcement from Elanco Animal Health ( (ELAN) ) is now available.

On May 16, 2025, Elanco Animal Health held its annual meeting of shareholders where all board-nominated directors were elected for a one-year term. Shareholders ratified Ernst & Young LLP as the independent accounting firm for 2025, approved executive compensation, and decided on an annual advisory vote on executive compensation until 2031, aligning with the board’s recommendation.

The most recent analyst rating on (ELAN) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Elanco Animal Health stock, see the ELAN Stock Forecast page.

Spark’s Take on ELAN Stock

According to Spark, TipRanks’ AI Analyst, ELAN is a Outperform.

Elanco Animal Health is well-positioned with strong financial resilience and positive earnings call outcomes, highlighting growth and innovation. The technical analysis indicates a bullish trend, though caution is advised due to overbought conditions. Valuation is moderate, with potential for growth in light of strategic initiatives. Corporate events underscore a focus on innovation, enhancing the company’s growth trajectory.

To see Spark’s full report on ELAN stock, click here.

More about Elanco Animal Health

Elanco Animal Health Incorporated operates in the animal health industry, providing products and services focused on improving animal health and well-being.

Average Trading Volume: 5,796,938

Technical Sentiment Signal: Buy

Current Market Cap: $6.57B

Find detailed analytics on ELAN stock on TipRanks’ Stock Analysis page.